Research Scientist ; Assistant Professor of Pediatrics
Children's Hospital of Philadelphia
Dr. De Raedt researches pediatric high grade glioma development and aims to understand the involvement of crucial pathways. He investigates pathway interaction, and explores ways to develop therapies through analyzing human tumors, performing cellular studies, and developing accurate mouse models. This allows Dr. De Raedt and his team to perform novel pre-clinical studies that can lead to clinical trials.
Elucidating the Role of Driver Mutations in Pediatric High Grade Glioma
High grade pediatric brain tumors (pHGG) are a devastating disease with a median survival of only 9-15 months. Importantly, pHGG represent the greatest cause of cancer related death in children under 19 years of age even though the overall incidence is low (1.78/100,000). In recent years it has b
Thomas De Raedt
High-grade glioma/astrocytoma (WHO grade III/IV)
High-grade Gliomas (HGG) in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric specific HGG preclinical models. These models are needed to help test the effective